[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ZA9610426B - Pharmaceutical composition - Google Patents

Pharmaceutical composition

Info

Publication number
ZA9610426B
ZA9610426B ZA9610426A ZA9610426A ZA9610426B ZA 9610426 B ZA9610426 B ZA 9610426B ZA 9610426 A ZA9610426 A ZA 9610426A ZA 9610426 A ZA9610426 A ZA 9610426A ZA 9610426 B ZA9610426 B ZA 9610426B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical composition
pharmaceutical
composition
Prior art date
Application number
ZA9610426A
Inventor
Josephine Joan Chri Ferdinando
Keith Graeme Hutchison
Roya Parker
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of ZA9610426B publication Critical patent/ZA9610426B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
ZA9610426A 1995-12-12 1996-12-11 Pharmaceutical composition ZA9610426B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9525194.8A GB9525194D0 (en) 1995-12-12 1995-12-12 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
ZA9610426B true ZA9610426B (en) 1997-06-23

Family

ID=10785178

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9610426A ZA9610426B (en) 1995-12-12 1996-12-11 Pharmaceutical composition

Country Status (4)

Country Link
AU (1) AU1039097A (en)
GB (1) GB9525194D0 (en)
WO (1) WO1997021440A1 (en)
ZA (1) ZA9610426B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
RU2004102393A (en) * 2001-07-07 2005-03-27 Астразенека Аб (Se) PHARMACEUTICAL COMPOSITION FOR INTRAMUSCULAR INTRODUCTION OF A FULVESTRANT
CA2492079C (en) 2002-07-24 2012-01-10 Schering Aktiengesellschaft Microbiological processes for the production of 7 alpha-substituted 11 alpha-hydroxy steroids
DE10247399A1 (en) * 2002-10-08 2004-04-29 Schering Ag Pharmaceutical preparations, use of this preparation and methods for increasing the bioavailability of drugs to be administered orally
WO2007033434A1 (en) * 2005-09-26 2007-03-29 Hospira Australia Pty Ltd Fulvestrant formulation
KR20100121505A (en) * 2008-03-07 2010-11-17 싸이도우스 엘엘씨. Fulvestrant formulations
CA2779005A1 (en) 2009-11-09 2011-05-12 Capsugel Belgium Nv Delivery carrier
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
CN108883118B (en) 2016-04-06 2021-06-15 富士胶片株式会社 Pharmaceutical composition

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs

Also Published As

Publication number Publication date
GB9525194D0 (en) 1996-02-07
AU1039097A (en) 1997-07-03
WO1997021440A1 (en) 1997-06-19

Similar Documents

Publication Publication Date Title
HU9601698D0 (en) Pharmaceutical composition
HUP9802999A3 (en) Pharmaceutical composition containing n-propargyl-1-aminoindan
ZA967827B (en) Pharmaceutical compositions
GB9519667D0 (en) Pharmaceutical composition
ZA962214B (en) Pharmaceutical composition
ZA963590B (en) Pharmaceutical composition
EG24294A (en) Pharmaceutical compositions
GB9506382D0 (en) Pharmaceutical compositions
GB9513972D0 (en) Pharmaceutical compositions
ZA96525B (en) Novel pharmaceutical compositions
ZA9610426B (en) Pharmaceutical composition
GB9502695D0 (en) Pharmaceutical composition
ZA964193B (en) Pharmaceutical composition
HU9602822D0 (en) Pharmaceutical composition
ZA963591B (en) Pharmaceutical composition
ZA95736B (en) Pharmaceutical composition
HUP9602732A2 (en) Pharmaceutical composition comprising lanperisone
GB9517063D0 (en) Pharmaceutical composition
GB9505368D0 (en) Pharmaceutical composition
ZA9510132B (en) Pharmaceutical composition
HU9903430D0 (en) Pharmaceutical composition
GB9519748D0 (en) Pharmaceutical composition
GB9515723D0 (en) Pharmaceutical composition
GB9505369D0 (en) Pharmaceutical composition
GB9515208D0 (en) Pharmaceutical composition